A new randomized double blind trial of both men and women with NAFLD (Nonalcoholic fatty liver disease) found positive results for supplemental coenzyme Q10. NAFLD describes a disease of the liver that is characterized by fat accumulation in the liver, enlargement of the liver and increased serum liver enzyme levels. Increase inflammation also accompanies this disease.
41 individuals with mild to moderate NAFLD participated in this study. 20 people received a daily 100 mg dose of CoQ10 for 12 weeks. The remainder of the participants received a placebo. Both before and after the study period markers of inflammation (C-reactive protein and tumor necrosis factor), liver enzymes and NAFLD grade (percentage of liver cells with fat droplets) were measured.
Participants in the CoQ10 group showed reductions in inflammation markers in comparison with the placebo group as well as in comparison to their own CoQ10 group levels at the onset of the study. In addition liver enzymes were lower at the end of the study compared to baseline in the CoQ10 group. Improvements in the NAFLD grades were also seen in the CoQ10 group.
CoQ10 supplementation was seen as a good therapy for systemic inflammation reduction in addition to others therapies used to treat this disease. Further studies are needed.
ASK US. WE KNOW. NOBODY KNOWS NUTRITION LIKE WE DO. NOBODY !